Guillermo Montalban‐Bravo

The University of Texas MD Anderson Cancer Center

Medicine

Pilot corpus only

This score is computed over theSindex pilot corpus and does not cover the full scientific literature. Scores are relative to papers we have ingested — papers, authors, and institutions outside the pilot are not represented. Methodology.

Top 100%percentile

0Author DataRank

Indexed papers

0in pilot corpus

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Papers

Driven by 40 papers. Top paper: “10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial”.

10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial

The Lancet Haematology(2020)10.1016/s2352-3026(20)30210-6

N/A

6.4DataRank · unranked

334 citations

Abhishek Maiti, Caitlin R. Rausch, Naveen Pemmaraju, Kiran Naqvi, Naval Daver +34 more

Prognostic value of measurable residual disease after venetoclax and decitabine in acute myeloid leukemia

Blood Advances(2021)10.1182/bloodadvances.2020003717

N/A

3.2DataRank · unranked

82 citations

Courtney D. DiNardo, Sa A. Wang, Jeffrey L. Jorgensen, Tapan M. Kadia, Naval Daver +28 more

Azacitidine, Venetoclax, and Gilteritinib in Newly Diagnosed and Relapsed or Refractory FLT3-Mutated AML

Journal of Clinical Oncology(2024)10.1200/jco.23.01911

N/A

2.7DataRank · unranked

152 citations

Naval Daver, Courtney D. DiNardo, Tapan M. Kadia, Lewis Nasr, Walid Macaron +19 more

Stem cell architecture drives myelodysplastic syndrome progression and predicts response to venetoclax-based therapy

Nature Medicine(2022)10.1038/s41591-022-01696-4

N/A

2.2DataRank · unranked

83 citations

Hui Yang, Feiyang Ma, Guillermo Montalban‐Bravo, Natthakan Thongon, Valentina Marchica +33 more

Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants

American Journal of Hematology(2023)10.1002/ajh.27070

N/A

1.6DataRank · unranked

48 citations

Sanam Loghavi, Yoheved Gerstein, Alexandre Bazinet, Koji Sasaki, Kelly S. Chien +19 more

A phase 1/2 study of azacitidine, venetoclax and pevonedistat in newly diagnosed secondary AML and in MDS or CMML after failure of hypomethylating agents

Journal of Hematology & Oncology(2023)10.1186/s13045-023-01476-8

N/A

1.3DataRank · unranked

51 citations

Muharrem Müftüoğlu, Faustine Ong, Lewis Nasr, Walid Macaron, Guillermo Montalban‐Bravo +22 more

A phase 1/2 study of mini-hyper-CVD plus venetoclax in patients with relapsed/refractory acute lymphoblastic leukemia

Blood Advances(2024)10.1182/bloodadvances.2023012231

N/A

0.940DataRank · unranked

34 citations

Elias Jabbour, Nitin Jain, Jayastu Senapati, Lewis Nasr, Fadi Haddad +18 more

Natural killer cells’ functional impairment drives the immune escape of pre-malignant clones in early-stage myelodysplastic syndromes

Nature Communications(2025)10.1038/s41467-025-58662-0

N/A

0.321DataRank · unranked

7 citations

Irene Gañán‐Gómez, Bijender Kumar, Natthakan Thongon, Feiyang Ma, Kelly S. Chien +35 more

Outcomes and Patterns of Relapse of NPM1 Mutated Acute Myeloid Leukemia Treated With Venetoclax Based Therapies

American Journal of Hematology(2025)10.1002/ajh.70046

N/A

0.245DataRank · unranked

4 citations

Sanam Loghavi, Alexandre Bazinet, Álex Bataller, Ian Bouligny, Naval Daver +15 more

Omacetaxine and venetoclax in relapsed/refractory acute myeloid leukemia or myelodysplastic syndrome with mutant RUNX1

Blood Neoplasia(2025)10.1016/j.bneo.2025.100145

N/A

0.104DataRank · unranked

1 citations

Wei‐Ying Jen, Guillermo Montalban‐Bravo, Xuemei Wang, Sanam Loghavi, Sravanthi Lavu +15 more

Evolutionary action score identifies a subset of TP53 mutated myelodysplastic syndrome with favorable prognosis

Blood Cancer Journal(2021)10.1038/s41408-021-00446-y

N/A

0DataRank · unranked

10 citations

Guillermo Montalban‐Bravo, Panagiotis Katsonis, Koji Sasaki, Caleb A. Class, Elias Jabbour +26 more

Impact of frontline treatment approach on outcomes in patients with secondary AML with prior hypomethylating agent exposure

Journal of Hematology & Oncology(2022)10.1186/s13045-022-01229-z

N/A

0DataRank · unranked

32 citations

Sangeetha Venugopal, Wei Qiao, Tapan M. Kadia, Farhad Ravandi, Walid Macaron +18 more

Phase II study of lower-intensity frontline therapy for newly diagnosed patients with AML who are unfit or otherwise not eligible for frontline clinical trials.

Journal of Clinical Oncology(2022)10.1200/jco.2022.40.16_suppl.e19028

N/A

0DataRank · unranked

0 citations

Elias Jabbour, Naveen Pemmaraju, Guillermo Montalban‐Bravo, Kelly S. Chien, Naval Daver +12 more

Venetoclax for Acute Myeloid Leukemia in Pediatric Patients: A Texas Medical Center Experience

Cancers(2023)10.3390/cancers15071983

N/A

0DataRank · unranked

33 citations

Amber Gibson, Jiasen He, David McCall, Michael Roth, César Núnêz +23 more

Targeting DNA2 Overcomes Metabolic Reprogramming in Multiple Myeloma

bioRxiv (Cold Spring Harbor Laboratory)(2023)10.1101/2023.02.22.529457

N/A

0DataRank · unranked

1 citations

Feiyang Ma, Pamela Lockyer, Natalia Baran, Jintan Liu, C. Ellen Jackson +27 more

Validation of the Prognostic Risk Signatures for Older Patients with Acute Myeloid Leukemia Treated with Hypomethylating Agents and Venetoclax

Blood(2023)10.1182/blood-2023-182841

N/A

0DataRank · unranked

0 citations

Alexandre Bazinet, Courtney D. DiNardo, Gautam Borthakur, Nicholas J. Short, Elias Jabbour +12 more

A Phase Ib, Open-Label Study of Add on Therapy with CK0804 in Participants with Myelofibrosis and Suboptimal Response to Ruxolitinib

Blood(2023)10.1182/blood-2023-188051

N/A

0DataRank · unranked

0 citations

Meixian Huang, Sharon Bledsoe, Naveen Pemmaraju, Tapan M. Kadia, Prithviraj Bose +10 more

Targeting MCL1-driven anti-apoptotic pathways overcomes blast progression after hypomethylating agent failure in chronic myelomonocytic leukemia

Cell Reports Medicine(2024)10.1016/j.xcrm.2024.101585

N/A

0DataRank · unranked

14 citations

Natthakan Thongon, Juan José Rodríguez‐Sevilla, Feiyang Ma, Irene Gañán‐Gómez, Hui Yang +16 more

Hematopoietic stem cells with granulo-monocytic differentiation state overcome venetoclax sensitivity in patients with myelodysplastic syndromes

Nature Communications(2024)10.1038/s41467-024-46424-3

N/A

0DataRank · unranked

10 citations

Irene Gañán‐Gómez, Feiyang Ma, Kelly S. Chien, Mónica Del Rey, Sanam Loghavi +13 more

Artificial Intelligence Assessment of Chest Radiographs for COVID-19

Clinical Lymphoma Myeloma & Leukemia(2024)10.1016/j.clml.2024.11.013

N/A

0DataRank · unranked

2 citations

Guillermo Garcia‐Manero, Masayuki Nigo, Elias Jabbour, Farhad Ravandi, William G. Wierda +14 more

Phase 1b/2 Study of Magrolimab (Magro), Azacitidine (AZA) and Venetoclax (VEN) in Patients (pts) with Newly Diagnosed (ND) Older/Unfit or High Risk Acute Myeloid Leukemia (AML) and Relapsed Refractory (R/R) AML: Final Clinical Data and Genomic Markers of Resistance/Relapse

Blood(2024)10.1182/blood-2024-203706

N/A

0DataRank · unranked

5 citations

Jayastu Senapati, Sanam Loghavi, Patrick K. Reville, Bofei Wang, Tapan M. Kadia +21 more

Early Obinutuzumab Significantly Increases Bone Marrow Undetectable MRD (10-4 sensitivity) (uMRD4) Rate When Combined with Acalabrutinib and Venetoclax in a Randomized Phase II Trial for Treatment Naïve CLL

Blood(2024)10.1182/blood-2024-211110

N/A

0DataRank · unranked

2 citations

Philip A. Thompson, Jan A. Burger, Musa Yılmaz, Nitin B. Jain, Tapan M. Kadia +23 more

Landscape and Clinicopathologic Features of RAS Pathway Mutations in Chronic Myelomonocytic Leukemia

Blood(2024)10.1182/blood-2024-208890

N/A

0DataRank · unranked

1 citations

Kelly S. Chien, Sanam Loghavi, Rashmi Kanagal‐Shamanna, Anuya Natu, Mark E. Gurney +22 more

Safety and Efficacy of G-CSF with Intensive Chemotherapy in Newly Diagnosed Acute Myeloid Leukemia: A Subgroup Analysis of the Phase II Trial of Venetoclax in Combination with Cladribine, Idarubicin, and Cytarabine

Blood(2024)10.1182/blood-2024-203938

N/A

0DataRank · unranked

1 citations

Hagop M. Kantarjian, Musa Yılmaz, Naval Daver, Gautam Borthakur, Courtney D. DiNardo +15 more

Outcomes of Adult Patients with Newly Diagnosed IDH-Mutated Acute Myeloid Leukemia Receiving Intensive Chemotherapy Plus Venetoclax

Blood(2024)10.1182/blood-2024-207413

N/A

0DataRank · unranked

1 citations

Jennifer Marvin‐Peek, Marina Konopleva, Gautam Borthakur, Naval Daver, Hussein A. Abbas +21 more

A Phase II Trial of Azacitidine with Ipilimumab, Nivolumab, or Ipilimumab and Nivolumab with or without Azacitidine in Relapsed or Refractory Myelodysplastic Syndrome

Blood(2024)10.1182/blood-2024-205186

N/A

0DataRank · unranked

0 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado Valero +15 more

Azacitidine, Venetoclax, and Magrolimab in Newly Diagnosed and Relapsed Refractory Acute Myeloid Leukemia: Phase Ib/II Study and Correlative Analysis

Clinical Cancer Research(2025)10.1158/1078-0432.ccr-25-0229

N/A

0DataRank · unranked

15 citations

Jayastu Senapati, Hagop M. Kantarjian, Bofei Wang, Patrick K. Reville, Sanam Loghavi +21 more

MECOM fusion partner and bone marrow blast percentage influence outcomes of patients with MECOM rearranged acute myeloid leukaemia

British Journal of Haematology(2025)10.1111/bjh.70171

N/A

0DataRank · unranked

3 citations

Guojun Tang, Eitan Kugler, Jennifer Croden, Koji Sasaki, Alexandre Bazinet +20 more

VEN in combination with 10-day DEC in newly diagnosed elderly or relapsed/refractory acute myeloid leukemia, and high-risk myelodysplastic syndrome: long term follow-up of a phase 2 trial

Blood Cancer Journal(2025)10.1038/s41408-025-01265-1

N/A

0DataRank · unranked

1 citations

Courtney D. DiNardo, Abhishek Maiti, Naveen Pemmaraju, Maro Ohanian, Naval Daver +19 more

Prognostic and therapeutic impacts of mutant TP53 variant allelic frequency in newly diagnosed acute myeloid leukemia

Blood Advances(2020)10.1182/bloodadvances.2020003120

N/A

0DataRank · unranked

182 citations

Guillermo Montalban‐Bravo, Hyunsoo Hwang, Jing Ning, Miguel Franquiz, Rashmi Kanagal‐Shamanna +12 more

A phase II trial of azacitidine with ipilimumab, nivolumab, or ipilimumab and nivolumab in previously untreated myelodysplastic syndrome

Haematologica(2025)10.3324/haematol.2024.286559

N/A

0DataRank · unranked

2 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Naval Daver, Elias Jabbour, Yesid Alvarado +19 more

Outcomes of relapsed or refractory acute myeloid leukemia after frontline hypomethylating agent and venetoclax regimens

Haematologica(2020)10.3324/haematol.2020.252569

N/A

0DataRank · unranked

174 citations

Caitlin R. Rausch, Jörge E. Cortes, Naveen Pemmaraju, Naval Daver, Farhad Ravandi +30 more

Genomic context and TP53 allele frequency define clinical outcomes in TP53-mutated myelodysplastic syndromes

Blood Advances(2020)10.1182/bloodadvances.2019001101

N/A

0DataRank · unranked

133 citations

Rashmi Kanagal‐Shamanna, Christopher B. Benton, Caleb A. Class, Kelly S. Chien, Koji Sasaki +17 more

Targeted next-generation sequencing of circulating cell-free DNA vs bone marrow in patients with acute myeloid leukemia

Blood Advances(2020)10.1182/bloodadvances.2019001156

N/A

0DataRank · unranked

43 citations

Keyur P. Patel, Maher Albitar, Miguel Franquiz, Rajyalakshmi Luthra, Rashmi Kanagal‐Shamanna +15 more

Natural history of newly diagnosed myelodysplastic syndrome with isolated inv(3)/t(3;3)

American Journal of Hematology(2020)10.1002/ajh.25991

N/A

0DataRank · unranked

6 citations

Guillermo Montalban‐Bravo, Rashmi Kanagal‐Shamanna, Elias Jabbour, Farhad Ravandi, Tapan M. Kadia +13 more

Only SF3B1 Mutation involving K700E (And Not Other Codons), Independently Predicts Overall Survival in Myelodysplastic Syndromes

bioRxiv (Cold Spring Harbor Laboratory)(2020)10.1101/2020.09.04.283598

N/A

0DataRank · unranked

0 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Elias Jabbour, Carlos E. Bueso‐Ramos, Yue Wei +14 more

Triplet therapy with venetoclax, FLT3 inhibitor and decitabine for FLT3-mutated acute myeloid leukemia

Blood Cancer Journal(2021)10.1038/s41408-021-00410-w

N/A

0DataRank · unranked

126 citations

Courtney D. DiNardo, Naval Daver, Caitlin R. Rausch, Farhad Ravandi, Tapan M. Kadia +20 more

Hematopoiesis under telomere attrition at the single-cell resolution

Nature Communications(2021)10.1038/s41467-021-27206-7

N/A

0DataRank · unranked

36 citations

Feiyang Ma, Andrea Santoni, Matteo Marchesini, Elena Fiorini, Ashley Rose +20 more

Only SF3B1 mutation involving K700E independently predicts overall survival in myelodysplastic syndromes

Cancer(2021)10.1002/cncr.33745

N/A

0DataRank · unranked

32 citations

Guillermo Montalban‐Bravo, Koji Sasaki, Faezeh Darbaniyan, Elias Jabbour, Carlos E. Bueso‐Ramos +13 more

Activity of venetoclax-based therapy in chronic myelomonocytic leukemia

Leukemia(2021)10.1038/s41375-021-01240-2

N/A

0DataRank · unranked

31 citations

Danielle Hammond, Courtney D. DiNardo, Marina Konopleva, Gautam Borthakur, Nicholas J. Short +15 more